Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.59 |
| ▸ | PPARG | P37231 | 13/20 | 0.59 |
| ▸ | PPARA | Q07869 | 12/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271394 | 0.90 | PPARD (0.51) | PPARDPPARGPPARACYP2C9KDM4E | |
| SCHEMBL10220168 | 0.88 | PPARD (0.71) | PPARDPPARGPPARACYP2C9 | |
| SCHEMBL10220182 | 0.86 | PPARD (0.73) | PPARDPPARGPPARA | |
| SCHEMBL10220390 | 0.86 | PPARD (0.75) | PPARDPPARGPPARAKMT2A | |
| SCHEMBL10220174 | 0.85 | PPARD (0.79) | PPARDPPARGPPARACYP2C9CSNK1D | |
| SCHEMBL10220166 | 0.83 | PPARD (0.78) | PPARDPPARGPPARA | |
| SCHEMBL10220629 | 0.82 | PPARD (0.80) | PPARDPPARGPPARAKMT2ACSNK1D | |
| SCHEMBL10219908 | 0.80 | PPARD (0.60) | PPARDPPARGPPARACYP2C9GAA | |
| SCHEMBL10221451 | 0.79 | PPARD (0.82) | PPARDPPARGPPARACYP2C9 | |
| SCHEMBL10271204 | 0.78 | PPARD (0.93) | PPARDPPARGPPARACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.